| External factors: | MHY2233 |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay//IP//qRT-PCR//western blot//Annexin V binding assay |
| Description: | The results show that MHY2233 treatment significantly decreased the percentage of SA-β-gal-positive cells concentration-dependently. The results show that MHY2233 and resveratrol significantly reduced the percentage of apoptotic cells, whereas the percentage was increased by EX527 .MHY2233 treatment also decreased the mRNA levels of various SASPs, namely, IL-6, IL-8, IL-1α, and IL-1β. MHY2233 also increased the phosphorylation of eNOS on serine 1177 .treatment with MHY2233 decreased the mRNA levels of p16, p53, and p21. |
| Regulatory pathway: | STAT1 |
| R-EF-Pathway: | Upregulation |
| Official symbol(s): | STAT1 |
| Pathway experiment: | Western blot//qRT-PCR |
| Pathway description: | SIRT1 protein and mRNA levels were assessed in EPCs after concentration-dependent treatment with MHY2233. SIRT1 protein and mRNA levels both were upregulated with increasing concentrations of MHY2233 .The mRNA and protein levels of SIRT1 were increased by MHY2233 and resveratrol, but were decreased by EX527. |
Annotation: